-
公开(公告)号:US11638711B2
公开(公告)日:2023-05-02
申请号:US16982281
申请日:2019-03-18
IPC分类号: A61K31/4709 , A61K9/06 , A61K47/10 , A61K47/12 , A61P17/10 , A61P17/00 , A61P17/04 , A61P31/04 , A61K31/573 , A61K9/00 , A61K31/047 , A61K31/085 , A61K31/355 , A61K47/44
摘要: The present invention relates to a composition for topical application comprising a polyaphron dispersion, the polyaphron dispersion comprising a continuous aqueous phase and at least one discontinuous oil phase, wherein the polyaphron dispersion comprises calcipotriol, betamethasone dipropionate, alpha-tocopherol and butylated hydroxyanisole, and wherein the composition has a pH of 7.75±0.5.
-
公开(公告)号:US11638692B2
公开(公告)日:2023-05-02
申请号:US17965253
申请日:2022-10-13
发明人: Indu Muni , Peter Mione , Anisa Gandhi , Cristina LeChiara
摘要: The invention relates to stable vancomycin hydrochloride powder for oral liquid formulations. Also provided herein are methods of using vancomycin oral liquid formulations for the treatment of certain diseases such as Clostridium difficile pseudomembranous colitis and Staphylococcal enterocolitis as well as kits and related products thereof.
-
公开(公告)号:US20230126688A1
公开(公告)日:2023-04-27
申请号:US17929232
申请日:2022-09-01
申请人: AMGEN INC.
发明人: Christopher James Sloey , Jason Ko , Tiansheng Li
IPC分类号: A61K47/12 , A61K47/22 , A61K39/395 , A61K9/00 , A61K38/18
摘要: The present invention relates to stable aqueous protein formulations. In particular, disclosed herein are therapeutic protein formulations suitable for parenteral administration having one or more antioxidants.
-
公开(公告)号:US20230126556A1
公开(公告)日:2023-04-27
申请号:US17624188
申请日:2021-06-29
发明人: Hai YE , Wenliang ZHOU , Jialin WANG , Ying XU , Tao MIN , Tian LV , Xingran CHEN
IPC分类号: C07C69/96 , C07C68/06 , A61K9/107 , A61K47/44 , A61K47/24 , A61K47/12 , A61K47/10 , A61K47/02
摘要: The application related to an ibuprofen ester derivative and an emulsion preparation thereof. A carboxyl group of racemic ibuprofen or S-ibuprofen is derivatized so that Compound N9 and a dextrorotatory enantiomer N9(S) thereof are obtained and further prepared into an emulsion preparation, which overcomes the problems of safety and compliance of patients existing in clinical application of existing ibuprofen/dexibuprofen injections and achieves the purposes of reducing vascular irritation, increasing clinical use approaches, and improving the stability of preparations in clinical applications.
-
公开(公告)号:US11633458B2
公开(公告)日:2023-04-25
申请号:US15035015
申请日:2014-11-07
IPC分类号: A61P37/04 , A61K38/21 , A61K38/08 , A61K31/353 , A61K45/06 , A61K31/7084 , A61K31/352 , A61K9/00 , A61K38/10 , A61K47/12
摘要: Toll-like receptor (TLR) agonists can induce chemokine production. We find that TLR2 and TLR6 are widely expressed on human melanoma cells, and that TLR2/6 agonists (MALP-2 or FSL-1) synergize with interferon-gamma (IFNγ) to induce production of CXCL10 from melanoma cells. Furthermore, melanoma cells and immune cells freshly isolated from surgical specimens also respond to TLR2/6 agonists +IFNγ by upregulating CXCL10 production, compared to treatment with either agent alone. It is also disclosed herein that these compounds are useful in inducing CLXL10 in other types of cancer. Collectively, these data identify a novel synergy of TLR2/6 agonists +IFNγ for inducing CXCL10 production directly from melanoma cells, raising the possibility that intratumoral administration of these agents may improve immune signatures in melanoma and have value in combination with other immune therapies, by supporting T-cell migration into melanoma metastases.
-
公开(公告)号:US11633438B2
公开(公告)日:2023-04-25
申请号:US16782372
申请日:2020-02-05
IPC分类号: A61K35/744 , C12N1/04 , A23K20/10 , A23L33/10 , A23L33/135 , A61K47/10 , A61K47/12 , A61K47/36 , C12N1/20
摘要: The present invention comprises the discovery and development of an effective cryoprotectant composition, without containing skim milk or any other animal-derived compounds, to achieve long-term stability of freeze-dried lactic acid bacteria (LAB), at different temperatures, whereby the retention of viability of the freeze-dried LAB after 6 months of storage, preferably after 9 months of storage, more preferably after 12 months of storage is more than 50%. The invention is in the field of producing freeze dried bacteria, in particular Lactic acid bacteria. More in particular, the invention relates to the use of a novel combination of cryoprotectants for increasing the viability of bacteria after freeze drying, improving the texture of the lyofilized cake for easy grinding and improving the long term stability of the freeze dried bacteria at different temperature conditions. The invention further relates to such freeze dried bacteria for use in food industry or in human or animal health applications. More in particular, the invention relates to the increased viability and long-term storage of recombinant bacteria capable of expressing heterologous proteins or peptides and administered to humans or animals for therapeutic or vaccination purposes.
-
公开(公告)号:US11628148B2
公开(公告)日:2023-04-18
申请号:US17739099
申请日:2022-05-07
IPC分类号: A61K31/132 , A61P17/02 , A61K9/00 , A61K9/06 , A61K47/10 , A61K47/12 , A61K47/20 , A61K47/38
摘要: A composition and method for treatment of brittle, broken, cracked or otherwise damaged nail and hoof plates. The composition is an aqueous-organic medium containing a non-covalent complex of a diamine and an organic acid or an aqueous-organic medium with a diamine alone.
-
公开(公告)号:US11628139B2
公开(公告)日:2023-04-18
申请号:US17198384
申请日:2021-03-11
发明人: Kiran Amancha , Chandeshwari Chilampalli , Thrimoorthy Potta , Ningxin Yan , Venkat R. Goskonda
IPC分类号: A61K9/00 , A61K31/485 , A61K9/08 , A61K47/12 , A61K47/10 , A61K47/02 , A61K47/18 , A61P25/36
摘要: The invention provides stable liquid formulations containing naloxone, a pharmaceutically acceptable salt or a derivative thereof. The invention further provides methods for treating opioid overdose, opioid dependence, and congenital insensitivity to pain with anhidrosis by administering the liquid formulations of the present invention intranasally to a patient in need thereof. Further, the invention provides a method of treating opioid dependence, opioid overdose, and congenital insensitivity to pain with anhidrosis by administering intranasally the naloxone formulations of the present invention.
-
公开(公告)号:US20230115881A1
公开(公告)日:2023-04-13
申请号:US17963926
申请日:2022-10-11
发明人: Charles M. COOK , Jiping FU , Yigang HE , Yan LOU , Rongzhen CHEN , Yan DONG
IPC分类号: C07C255/54 , C07C253/34 , A61K9/20 , A61K9/48 , A61K9/00 , A61K47/26 , A61K47/38 , A61K47/12 , A61K9/06 , A61K47/10 , A61K47/14 , C07C253/30 , A61K9/08
摘要: The present disclosure provides certain processes of making 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)-benzonitrile (Compound 1) and certain polymorphs thereof. Also provided are pharmaceutical compositions comprising a crystalline polymorph form of Compound 1 and processes for preparing such polymorph forms.
-
公开(公告)号:US20230115267A1
公开(公告)日:2023-04-13
申请号:US17911167
申请日:2021-03-10
发明人: Mi Gyeong KIM , Seung-ha LEE , Han Soo KIM , In Ae KIM , Na Young LEE , Soo Shin KIM , Ji Hyun KIM
IPC分类号: C07K16/24 , A61K31/4172 , A61K47/26 , A61K47/12
摘要: Provided is a liquid pharmaceutical composition having increased stability, and more particularly, a stable liquid pharmaceutical composition including a protein.
-
-
-
-
-
-
-
-
-